---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-24-000119"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:27:07.255235+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tarsus appoints Elizabeth Yeu as CMO; she resigns from board

## Summary
- Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.
- Annual base salary of $480,000, $25,000 signing bonus, and 45% annual incentive bonus.
- Granted 27,278 RSUs vesting 25% annually over four years, and option for 41,074 shares.
- Severance includes 12 months salary and benefits; accelerated vesting on change in control.
- Dr. Yeu previously served as board member since Dec 2021 and consulting Chief Medical Advisor.

## SEC filing metadata
- accession: 0001819790-24-000119
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/tars-20241101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-24-000119
- JSON: https://secwatch.observer/filing/0001819790-24-000119.json
- Plain text: https://secwatch.observer/filing/0001819790-24-000119.txt

## Key facts
- Executive change
  Elizabeth Yeu was appointed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On November 5, 2024, Tarsus Pharmaceuticals, Inc. (the "Company") announced the appointment of Elizabeth Yeu, M.D. as the Company's Chief Medical Officer, effective as of November 4, 2024 (the "Effective Date").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm
- Executive change
  Elizabeth Yeu resigned as Member of the Board of Directors at Tarsus Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: In connection with the appointment, on November 1, 2024, Dr. Yeu resigned as a member of the Company's board of directors (the "Board") and from the committees of the Board on which she served, each effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.